X4 Pharmaceuticals (NASDAQ:XFOR) Now Covered by Guggenheim

Guggenheim started coverage on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a research report report published on Monday, Marketbeat.com reports. The firm issued a buy rating and a $12.00 price target on the stock.

XFOR has been the topic of a number of other research reports. Stifel Nicolaus set a $10.00 target price on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 5th. Zacks Research lowered X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Finally, Wall Street Zen downgraded X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, X4 Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $28.88.

X4 Pharmaceuticals Stock Performance

XFOR opened at $4.15 on Monday. The company has a 50 day simple moving average of $3.65 and a two-hundred day simple moving average of $3.61. The company has a debt-to-equity ratio of 1.23, a current ratio of 5.65 and a quick ratio of 5.48. The firm has a market cap of $362.88 million, a P/E ratio of -0.41 and a beta of 0.43. X4 Pharmaceuticals has a 1-year low of $1.35 and a 1-year high of $10.67.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Indivisible Partners purchased a new stake in X4 Pharmaceuticals in the 4th quarter worth $40,000. Squarepoint Ops LLC bought a new stake in shares of X4 Pharmaceuticals in the fourth quarter worth about $50,000. Two Sigma Investments LP purchased a new stake in shares of X4 Pharmaceuticals in the third quarter worth about $47,000. Stifel Financial Corp purchased a new stake in shares of X4 Pharmaceuticals in the fourth quarter worth about $82,000. Finally, Virtu Financial LLC bought a new position in X4 Pharmaceuticals during the fourth quarter valued at approximately $90,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.